Compare ALLY & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLY | EXAS |
|---|---|---|
| Founded | 1919 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.0B |
| IPO Year | 2014 | N/A |
| Metric | ALLY | EXAS |
|---|---|---|
| Price | $42.69 | $101.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 20 |
| Target Price | $46.33 | ★ $76.38 |
| AVG Volume (30 Days) | 2.7M | ★ 10.3M |
| Earning Date | 01-21-2026 | 11-03-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | ★ 11.52 | N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $7,171,000,000.00 | $3,082,033,000.00 |
| Revenue This Year | $20.26 | $19.40 |
| Revenue Next Year | $14.12 | $13.51 |
| P/E Ratio | $25.36 | ★ N/A |
| Revenue Growth | 6.02 | ★ 14.47 |
| 52 Week Low | $29.52 | $38.81 |
| 52 Week High | $44.83 | $101.87 |
| Indicator | ALLY | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 89.74 |
| Support Level | $37.51 | $100.98 |
| Resistance Level | $41.77 | $101.43 |
| Average True Range (ATR) | 1.03 | 2.25 |
| MACD | 0.39 | 0.53 |
| Stochastic Oscillator | 93.52 | 97.74 |
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.